Reports Q1 revenue $18.52M vs. $11.1M last year. “We’ve transformed from a single-product, burn-only company into an integrated, multi-product platform positioned to lead in therapeutic acute wound care,” said Jim Corbett, Chief Executive Officer of AVITA Medical (RCEL). “With the February rollout of RECELL GO mini and the nationwide launch of Cohealyx on April 1, our portfolio now addresses a U.S. market opportunity that has expanded from $455 million to more than $3.5 billion. Our multi-product platform equips clinicians with innovative tools that integrate smoothly into existing workflows, and together with our commercial field transformation, they position AVITA for scalable, long-term growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- RCEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Avita Medical announces U.S. commercial launch of Cohealyx
- Avita Medical’s Strategic Expansion and Market Growth Potential: Analyst Buy Rating
- Avita Medical Boosts Production with New Agreement
- Avita Medical amends PermeaDerm distribution agreement with Stedical Scientific